Government-Owned Inventions; Availability for Licensing, 18833-18834 [2012-7419]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 60 / Wednesday, March 28, 2012 / Notices
Competitive Advantages:
• These T cell clones were isolated
and selected from the bulk TIL cultures
of the respective patients from which
they were derived due to their superior
reactivity to their TAA antigen.
• Significant data has been collected
on their characteristics, including
identification of the tumor associated
antigen and specific cancer peptide
recognized by the T cell receptor of each
clone.
Development Stage:
• Pre-clinical
• Clinical
• In vitro data available
• In vivo data available (human)
Inventors: Mark E. Dudley and Steven
A. Rosenberg (both of NCI).
Publications:
1. Dudley M, et al. Cancer regression
and autoimmunity in patients after
clonal repopulation with antitumor
lymphocytes. Science. 2002 Oct
25;298(5594):850–854. [PMID 12242449]
2. Dudley M, et al. Adoptive transfer
of cloned melanoma-reactive T
lymphocytes for the treatment of
patients with metastatic melanoma. J
Immunother. 2001 Jul–Aug;24(4):363–
373. [PMID 11565838]
Intellectual Property: HHS Reference
No. E–267–2010/0—Research Tool.
Patent protection is not being pursued
for this technology.
Related Technologies:
• HHS Reference No. E–057–1994—
elanoma Antigens and Their Use in
Diagnostic and Therapeutic Methods
• HHS Reference No. E–086–2001—
Peptides of a Melanoma Antigen and
Their Use in Diagnostic, Prophylactic,
and Therapeutic Methods
• HHS Reference No. E–106–2004—
Compositions Comprising T cell
Receptors and Methods of Use Thereof
• HHS Reference No. E–304–2006—
Modified T cell Receptors and Related
Materials and Methods
• HHS Reference No. E–059–2007—
gp100-specific T cell Receptors and
Related Materials and Methods
• HHS Reference No. E–312–2007—
Modified T cell Receptors and Related
Materials and Methods
• HHS Reference No. E–257–2008—
Melanoma Associated Peptide
Analogues and Vaccines Against
Melanoma
• HHS Reference No. E–261–2008—
Melanoma Associated Antigenic
Polypeptide, Epitopes Thereof and
Vaccines Against Melanoma
Licensing Contact: Samuel E. Bish,
Ph.D.; 301–435–5282;
bishse@mail.nih.gov.
VerDate Mar<15>2010
17:29 Mar 27, 2012
Jkt 226001
Dated: March 22, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–7420 Filed 3–27–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Personalized Body Weight Management
System Using Monitoring Devices and
Mathematical Models of Metabolism
Description of Technology: Attempts
to manage body weight are often
unsuccessful or only temporary. This is,
in part, due to antiquated dieting
methods that attempt to address calorie
consumption while ignoring metabolic
and physical changes. It is becoming
clear that personalized methods to
manage body weight must be developed.
Scientists at the NIH have developed
new methods for prescribing and
monitoring personalized weight
management interventions. The system
uses validated mathematical models of
human metabolism to set weight
management goals and predict
individual body weight outcomes in the
context of changing metabolic needs
and calorie consumption. The system
uses repeated monitoring of a patient’s
body weight to assess progress and
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
18833
provide specific feedback to the patient
and health care professional. Projected
outcomes and body weight goals can be
revised over time along with required
prescription modifications to meet the
body weight goals. The system is
integrated into a network of one or more
devices that may additionally monitor
various physiological parameters,
physical activities, food intake, or other
behaviors. Such an enhanced
personalized weight management
program has great promise in the
management of obesity.
Potential Commercial Applications:
• Devices—Weight management
diagnostic.
• Software for the integration of
multiple devices.
Competitive Advantages: Integrated
system provides feedback to health care
professional and patient with more
accurate predictors of weight loss
outcomes. Combined with other
devices, patient receives encouragement
to stay on track.
Inventor: Kevin D. Hall (NIDDK).
Publications:
1. Hall KD, Sacks G, Chandramohan
D, Chow CC, Wang YC, Gortmaker SL,
Swinburn BA. Quantification of the
effect of energy imbalance on
bodyweight. Lancet. 2011 378
(9793):826–837. [PMID 21872751]
2. Hall KD and Chow CC. Estimating
changes in free-living energy intake and
its confidence interval. Am J Clin Nutr.
2011 Jul;94(1):66–74. [PMID 21562087]
3. Hall KD. Predicting metabolic
adaptation, body weight change, and
energy intake in humans. Am J Physiol
Endocrinol Metab. 2010
Mar;298(3):E449–466. [PMID 19934407]
Intellectual Property: HHS Reference
No. E–063–2012/0—U.S. Provisional
Application No. 61/592,325 filed 30 Jan
2012.
Licensing Contact: Michael A.
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK Laboratory of Biological
Modeling is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Marguerite J. Miller at 301–496–
9003 or millermarg@niddk.nih.gov.
Direct Impact Spark Ionization (DISI)
Mass Spectrometry (MS) for
Identification of Microbes
Description of Technology: Generating
reproducible mass spectra from bacterial
samples in a timely fashion at
atmospheric pressure remained
problematic for many years. FDA/NCTR
E:\FR\FM\28MRN1.SGM
28MRN1
tkelley on DSK3SPTVN1PROD with NOTICES
18834
Federal Register / Vol. 77, No. 60 / Wednesday, March 28, 2012 / Notices
inventors designed a rapid mass
spectrometry device using direct impact
spark ionization source for microbial
analytes identification via spectral
pattern recognition. The device design
includes a rapid mass spectrometer
suitable for analyzing microbiological
samples that was earlier used to analyze
low volatile organic compounds. The
device employs a solid needle for
electrode discharge. It includes a gear
plate that introduces stainless steel pins
carrying bacterial samples. The pins
also act as counter electrodes and are
targeted by controlled arcs. The small
custom-made glass cylinder that is
meant to shut out oxygen and prevent
the introduction of ambient moisture
into the analyte is unique from other
DISI device. The examination revealed
enormous peak intensity and spectral
information with normal ionization
mode on the same instrument. This
device can be employed in fields such
as pathogen determination in clinical
settings, QA/QC (of drugs, food or
cosmetic ingredients), continuous
monitoring of (airborne) Biological
Warfare Agents and the like.
Potential Commercial Applications:
• Pathogen detection,
• QA/QC (of drugs, food or cosmetic
ingredients),
• Continuous monitoring of (airborne)
Biological Warfare Agents and the like.
Competitive Advantages:
• Rapid, specific, sensitive and
reproducible identification of
microbiological analytes.
• Systematic acquisition of
reproducible spectra among same
bacterial species.
• Whole cell analysis of food-borne
pathogens is rapid, safer and microreliable.
• Characteristic mass spectra
obtained and reproduced for food-borne
pathogens.
• Unique DISI device with gas
cylinder chamber.
Development Stage:
• Prototype.
• In vitro data available.
Inventors: Peter Alusta, Cameron
Dorey, Ryan Parker, Dan A. Buzatu, Jon
G. Wilkes (all of FDA/NCTR).
Intellectual Property: HHS Reference
No. E–258–2011/0—U.S. Patent
Application No. 13/271,182 filed 11 Oct
2011.
Related Technologies:
• HHS Reference No. E–169–2000/
0—U.S. Patent Application No. 09/
975,530 filed 10 Oct 2001.
• HHS Reference No. E–259–2011/
0—U.S. Provision Application No. 61/
564,926 filed 30 Nov 2011.
Licensing Contact: Michael A.
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
VerDate Mar<15>2010
17:29 Mar 27, 2012
Jkt 226001
Collaborative Research Opportunity:
The NCTR/FDA inventors are seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize this device. For
collaboration opportunities, please
contact Alice Y. Welch, Ph.D. at
Alice.Welch@fda.hhs.gov.
Method of Treating Hepatitis C Virus
Infection With a Small Molecule CHK2
Inhibitor
Description of Technology: DNA
damage sensors such as Checkpoint
Kinase 2 (Chk2) are key regulators of the
cellular DNA damage response that
limits cell-cycle progression in response
to DNA damage. It has been reported
that these DNA damage sensors also
play a key role in Hepatitis C virus
(HCV) replication. The subject
technology are small molecule CHK2
kinase inhibitors that have been shown
to have promising activity against HCV
replication. The compounds were
discovered by high throughput
screening of chemical libraries with
more than 150,000 compounds. These
novel compounds can potentially be
used in combination with other antiHCV drugs or interferon and represent
a novel target for treating HCV. In vitro
antiviral assay data, as well as
preliminary in vitro and in vivo
pharmokinetic data are available upon
request.
Potential Commercial Applications:
The subject technology can potentially
be developed into anti-HCV
therapeutics, particularly in
combination with other anti-HCV
therapeutics.
Competitive Advantages: The subject
technology represents a novel and
promising target for treating HCV
infection and thus, has the potential to
increase the efficacy of other HCV
antivirals that directly target HCV in a
multi-drug formulation. Furthermore,
since the subject technology targets a
cellular protein necessary for HCV
replication and not the virus itself, the
emergence of viral resistance against the
subject technology could be low or more
delayed.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: Yves G. Pommier, Robert H.
Shoemaker, Dominic A. Scudiero,
Andrew G. Jobson, David S. Waugh,
George T. Lountos (all of NCI)
Publications:
1. Jobson AG, et al. Identification of
a Bis-guanylhydrazone [4,4′Diacetyldiphenylurea-
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
bis(guanylhydrazone); NSC 109555] as a
novel chemotype for inhibition of Chk2
kinase. Mol Pharmacol 2007
Oct;72(4):876–884. [PMID 17616632]
2. Jobson AG, et al. Cellular inhibition
of checkpoint kinase 2 (Chk2) and
potentiation of camptothecins and
radiation by the novel Chk2 inhibitor
PV1019 [7-nitro-1H-indole-2-carboxylic
acid {4-[1-(guanidinohydrazone)-ethyl]phenyl}-amide]. J Pharmacol Exp Ther.
2009 Dec;331(3):816–826. [PMID
19741151]
3. Lountos GT, et al. Crystal structure
of checkpoint kinase 2 in complex with
NSC 109555, a potent and selective
inhibitor. Protein Sci. 2009
Jan;18(1):92–100. [PMID 19177354]
4. Lountos GT, et al. X-ray structures
of checkpoint kinase 2 in complex with
inhibitors that target its gatekeeperdependent hydrophobic pocket. FEBS
Lett. 2011Oct 20;585(20):3245–3249.
[PMID 21907711]
5. Lountos GT, et al. Structural
characterization of inhibitor complexes
with checkpoint kinase 2 (Chk2), a drug
target for cancer therapy. J Struct Biol.
2011 Dec;176(3):292–301. [PMID
21963792]
Intellectual Property: HHS Reference
No. E–224–2011/0—U.S. Provisional
Patent Application No. 61/551,742 filed
26 Oct 2011.
Related Technology: HHS Reference
No. E–211–2005/0—U.S. Patent
Application No. 11/989,737 filed 29 Jan
2008, with corresponding applications
in Europe, Canada, and Australia.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Dated: March 22, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–7419 Filed 3–27–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4057–
DR; Docket ID FEMA–2012–0002]
Kentucky; Amendment No. 5 to Notice
of a Major Disaster Declaration
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
This notice amends the notice
of a major disaster declaration for the
SUMMARY:
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 77, Number 60 (Wednesday, March 28, 2012)]
[Notices]
[Pages 18833-18834]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-7419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Personalized Body Weight Management System Using Monitoring Devices and
Mathematical Models of Metabolism
Description of Technology: Attempts to manage body weight are often
unsuccessful or only temporary. This is, in part, due to antiquated
dieting methods that attempt to address calorie consumption while
ignoring metabolic and physical changes. It is becoming clear that
personalized methods to manage body weight must be developed.
Scientists at the NIH have developed new methods for prescribing
and monitoring personalized weight management interventions. The system
uses validated mathematical models of human metabolism to set weight
management goals and predict individual body weight outcomes in the
context of changing metabolic needs and calorie consumption. The system
uses repeated monitoring of a patient's body weight to assess progress
and provide specific feedback to the patient and health care
professional. Projected outcomes and body weight goals can be revised
over time along with required prescription modifications to meet the
body weight goals. The system is integrated into a network of one or
more devices that may additionally monitor various physiological
parameters, physical activities, food intake, or other behaviors. Such
an enhanced personalized weight management program has great promise in
the management of obesity.
Potential Commercial Applications:
Devices--Weight management diagnostic.
Software for the integration of multiple devices.
Competitive Advantages: Integrated system provides feedback to
health care professional and patient with more accurate predictors of
weight loss outcomes. Combined with other devices, patient receives
encouragement to stay on track.
Inventor: Kevin D. Hall (NIDDK).
Publications:
1. Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker
SL, Swinburn BA. Quantification of the effect of energy imbalance on
bodyweight. Lancet. 2011 378 (9793):826-837. [PMID 21872751]
2. Hall KD and Chow CC. Estimating changes in free-living energy
intake and its confidence interval. Am J Clin Nutr. 2011 Jul;94(1):66-
74. [PMID 21562087]
3. Hall KD. Predicting metabolic adaptation, body weight change,
and energy intake in humans. Am J Physiol Endocrinol Metab. 2010
Mar;298(3):E449-466. [PMID 19934407]
Intellectual Property: HHS Reference No. E-063-2012/0--U.S.
Provisional Application No. 61/592,325 filed 30 Jan 2012.
Licensing Contact: Michael A. Shmilovich, Esq., CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK Laboratory of
Biological Modeling is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize this technology. For collaboration
opportunities, please contact Marguerite J. Miller at 301-496-9003 or
millermarg@niddk.nih.gov.
Direct Impact Spark Ionization (DISI) Mass Spectrometry (MS) for
Identification of Microbes
Description of Technology: Generating reproducible mass spectra
from bacterial samples in a timely fashion at atmospheric pressure
remained problematic for many years. FDA/NCTR
[[Page 18834]]
inventors designed a rapid mass spectrometry device using direct impact
spark ionization source for microbial analytes identification via
spectral pattern recognition. The device design includes a rapid mass
spectrometer suitable for analyzing microbiological samples that was
earlier used to analyze low volatile organic compounds. The device
employs a solid needle for electrode discharge. It includes a gear
plate that introduces stainless steel pins carrying bacterial samples.
The pins also act as counter electrodes and are targeted by controlled
arcs. The small custom-made glass cylinder that is meant to shut out
oxygen and prevent the introduction of ambient moisture into the
analyte is unique from other DISI device. The examination revealed
enormous peak intensity and spectral information with normal ionization
mode on the same instrument. This device can be employed in fields such
as pathogen determination in clinical settings, QA/QC (of drugs, food
or cosmetic ingredients), continuous monitoring of (airborne)
Biological Warfare Agents and the like.
Potential Commercial Applications:
Pathogen detection,
QA/QC (of drugs, food or cosmetic ingredients),
Continuous monitoring of (airborne) Biological Warfare
Agents and the like.
Competitive Advantages:
Rapid, specific, sensitive and reproducible identification
of microbiological analytes.
Systematic acquisition of reproducible spectra among same
bacterial species.
Whole cell analysis of food-borne pathogens is rapid,
safer and micro-reliable.
Characteristic mass spectra obtained and reproduced for
food-borne pathogens.
Unique DISI device with gas cylinder chamber.
Development Stage:
Prototype.
In vitro data available.
Inventors: Peter Alusta, Cameron Dorey, Ryan Parker, Dan A. Buzatu,
Jon G. Wilkes (all of FDA/NCTR).
Intellectual Property: HHS Reference No. E-258-2011/0--U.S. Patent
Application No. 13/271,182 filed 11 Oct 2011.
Related Technologies:
HHS Reference No. E-169-2000/0--U.S. Patent Application
No. 09/975,530 filed 10 Oct 2001.
HHS Reference No. E-259-2011/0--U.S. Provision Application
No. 61/564,926 filed 30 Nov 2011.
Licensing Contact: Michael A. Shmilovich, Esq., CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NCTR/FDA inventors are
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate or commercialize
this device. For collaboration opportunities, please contact Alice Y.
Welch, Ph.D. at Alice.Welch@fda.hhs.gov.
Method of Treating Hepatitis C Virus Infection With a Small Molecule
CHK2 Inhibitor
Description of Technology: DNA damage sensors such as Checkpoint
Kinase 2 (Chk2) are key regulators of the cellular DNA damage response
that limits cell-cycle progression in response to DNA damage. It has
been reported that these DNA damage sensors also play a key role in
Hepatitis C virus (HCV) replication. The subject technology are small
molecule CHK2 kinase inhibitors that have been shown to have promising
activity against HCV replication. The compounds were discovered by high
throughput screening of chemical libraries with more than 150,000
compounds. These novel compounds can potentially be used in combination
with other anti-HCV drugs or interferon and represent a novel target
for treating HCV. In vitro antiviral assay data, as well as preliminary
in vitro and in vivo pharmokinetic data are available upon request.
Potential Commercial Applications: The subject technology can
potentially be developed into anti-HCV therapeutics, particularly in
combination with other anti-HCV therapeutics.
Competitive Advantages: The subject technology represents a novel
and promising target for treating HCV infection and thus, has the
potential to increase the efficacy of other HCV antivirals that
directly target HCV in a multi-drug formulation. Furthermore, since the
subject technology targets a cellular protein necessary for HCV
replication and not the virus itself, the emergence of viral resistance
against the subject technology could be low or more delayed.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: Yves G. Pommier, Robert H. Shoemaker, Dominic A.
Scudiero, Andrew G. Jobson, David S. Waugh, George T. Lountos (all of
NCI)
Publications:
1. Jobson AG, et al. Identification of a Bis-guanylhydrazone [4,4'-
Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel
chemotype for inhibition of Chk2 kinase. Mol Pharmacol 2007
Oct;72(4):876-884. [PMID 17616632]
2. Jobson AG, et al. Cellular inhibition of checkpoint kinase 2
(Chk2) and potentiation of camptothecins and radiation by the novel
Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-
(guanidinohydrazone)-ethyl]-phenyl{time} -amide]. J Pharmacol Exp Ther.
2009 Dec;331(3):816-826. [PMID 19741151]
3. Lountos GT, et al. Crystal structure of checkpoint kinase 2 in
complex with NSC 109555, a potent and selective inhibitor. Protein Sci.
2009 Jan;18(1):92-100. [PMID 19177354]
4. Lountos GT, et al. X-ray structures of checkpoint kinase 2 in
complex with inhibitors that target its gatekeeper-dependent
hydrophobic pocket. FEBS Lett. 2011Oct 20;585(20):3245-3249. [PMID
21907711]
5. Lountos GT, et al. Structural characterization of inhibitor
complexes with checkpoint kinase 2 (Chk2), a drug target for cancer
therapy. J Struct Biol. 2011 Dec;176(3):292-301. [PMID 21963792]
Intellectual Property: HHS Reference No. E-224-2011/0--U.S.
Provisional Patent Application No. 61/551,742 filed 26 Oct 2011.
Related Technology: HHS Reference No. E-211-2005/0--U.S. Patent
Application No. 11/989,737 filed 29 Jan 2008, with corresponding
applications in Europe, Canada, and Australia.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
changke@mail.nih.gov.
Dated: March 22, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-7419 Filed 3-27-12; 8:45 am]
BILLING CODE 4140-01-P
